The efficacy and safety of Topiramate in the Treatment of Refractory Epilepsy in children in Paediatric Neurology clinic at Izzat Ali Shah Hospital

  • Shahzad Haider Wah Medical College
  • Kiran Pervaiz
  • Komal Noor
  • Madiha Fayyaz
  • Sajid Nazir
  • Lubna Ehtizaz
Keywords: Topiramate, Refractory Epilepsy, Generalised epilepsy, Focal epilepsy

Abstract

Objectives: This study has been performed to observe the efficacy & safety of Topiramate in refractory epilepsies in children in Pakistan.
Materials and Methods: A cross-sectional prospective consecutive series of children age between (1-14 years) with refractory epilepsy were recruited from the Paediatric Neurology clinic of Izzat Ali Shah Hospital. Epilepsy was classified into Generalized, Focal, and Unknown based on ILAE Classification. Topiramate was added in patients who were refractory to at least two anti-epileptic drugs. The outcome was recorded in four categories i.e total remission, >50% seizure reduction, <50% seizure reduction, and no improvement.
Results: Fifty-eight patients were enrolled in the study, but 5 patients were dropped out due to significant side effects. Most of the children were in the age group ranging from 5 to 10 years with predominant boys (n=32). The major type of epilepsy was 53% (n=28) was Unknown, while 36% (n=19) children had Generalized epilepsy and 11% (n=6) had Focal epilepsy. 25% children had total remission, 38% had >50% seizure reduction, 28% had < 50% seizure reduction and 9% had no improvement. Total remission was mostly seen in Focal epilepsy (50%) and least shown in Unknown type (14%) and the difference was significant (Chi-Square test p=0.039). Adverse effects to Topiramate were found in 33 (62%) of the total enrolled patients. Common adverse effects were weight loss in 14(26%), poor appetite in 13(24.5%), and behavioral issues in 6(22.5%) children.
Conclusion: Topiramate is an effective anti-epileptic drug (AED) in refractory epilepsy especially with Focal and Generalized onset but is not as effective in other types of Refractory epilepsy. Weight loss and poor appetite were the commonest adverse effects that were reversible after dose reduction.

References

1. Shank RP, Gardocki JF, Streeter AJ, Mayanoff BE. An overview of the preclinical aspects of topiramate, pharmacology, pharmacokinetics, and mechanism of action. Epilepsia 2000;41(Suppl. 1):S21-4.
2. White HS, Brown SD, Woodhead JH, Skeen GA, Wolf HH. Topiramate modulates GABA-evoked currents in murine cortical neurons by a non benzodiazepine mechanism. Epilepsia 2000;41(Suppl. 1):S17-20.
3. Gibbs JW, Sombati S, DeLorenzo RJ, Coulter DA. Cellular action of Topiramate : blockade of kainite-evoked inward current in cultured hippocampal neurons. Epilepsia 2000;41(Suppl. 1):S10-6.
4. Khalil N Y, Wani TA. In profiles of drug substances , excipients and related methodology, 2019
5. Glauber TA, Clark PO, Strawsburg R.A Pilot study of Topiramate in the
treatment of infantile spasms, Epilepsia 1998;39:1324-8.
6. Thiji J, Verhelst H, Vancoster R. Retrospective study of Topiramate in a pedriatic population with interactive epilepsy showing promising effects in the west syndrome patients. Acta Neurol Belg 2001;101:171-6.
7. Watemberg N, Goldberg Stern H, Ben Zeev B ,Berger I,Strausberg R, Kivity S,etc always. Clinical experience with open label Topiramate use in infants younger than 2 years of age.J Child Neurol 2003;(18):258-62.
8. Sachdeo RC, Glauser TA, Ritter F, Reife F, Lim P, Pledger G.A double blind, randomized trial of Topiramate in Lennox Gastaut syndrome.Neurology 1999;52:1882-7.
9. Coppola G, Caliendo G, Vegiotti P, Romeo A, Tortorella G, De Marco P et al. Topiramate as add on drug in children, adolescents and young adult with Lennox Gastaut syndrome: an Italian multicentric study. Epilepsy Res 2002;51:147-53.
10. Alva Monday’s E, Ruiz Ruiz A. The value of Topiramate used with conventional schemes as an adjunctive therapy in the treatment of Lennox Gastaut Syndrome. Rev Neurol 2003;35:453-7.
11. Biton V, Montouris GD, Ritter F, Rivielllo JJ, Reife R, Lim P, et al. A randomized placebo-controlled study of Topiramate in primary generalized tonic clonic seizures. Neurology 1999;52:1330-7.
12. Faught E. Efficacy of topiramate as adjunctive therapy in refractory partial seizures: United State trial experience. Epilepsia 2000;41(Suppl. 1):S24-7
13. Ben-Menachem E. Clinical efficacy of topiramate as add on therapy in refractory partial epilepsy: the European experience. Epilepsia 1997;38(Suppl. 1):S28-30
14. Kwan, P., Arzimanoglou, A., Berg, A.T., Brodie, M.J., Allen Hauser, W., Mathern, G., Moshé, S.L., Perucca, E., Wiebe, S. and French, J. (2010), Definition of drug resistant epilepsy: Consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia, 51: 1069-1077.
15. Al Ajlouni S, Shorman A, Daoud AS. The efficacy and side effects of topiramate on refractory epilepsy in infants and young children: a multi-center clinical trial. Seizure. 2005 Oct;14(7):459-63. doi: 10.1016/j.seizure.2005.07.009. Epub 2005 Aug 8. PMID: 16087357.
16. Hassan A, Jan MM, Shabat AO. Topiramate for the treatment of intractable childhood epilepsy. Neurosciences 2003;8:233-6.
17. Ritter F ,Glause TA ,,Elterman RD, Wyllie E. Effectiveness, tolerability and safety of Topiramate in children with partial onset seizures. Epilepsia 2000;41:S82-5.
18. Coppola G, Caliendo G, Veggiotti P, Romeo A, Tortorella G, De Marco P, et al.. Topiramate in refractory partial onset seizures in children, adolescents and young adults : a multicentric open trial. Epilepsy Res 2001;43:255-60.
19. Glauser TA, Levisohn PM, Ritter F ,Sachdeo RC. Topiramate in Lennox Gastaut Syndrome: open label treatment of patients completing a randomized controlled trial .Epilepsia 2000;41:S86–90.
20. Kato T, Nakata M, Ide M, Saito K, Yoshida T, Awaya T, Heike T. [Efficacy and tolerability of topiramate, lamotrigine, and levetiracetam in children with refractory epilepsy]. No To Hattatsu. 2015 Sep;47(5):354-9. Japanese. PMID: 26502652.
21. Unalp A, Uran N, Hizli T, Ozturk A. Topiramate as a long-term therapy in children with refractory epilepsy. Neurosciences (Riyadh). 2008 Oct;13(4):391-4. PMID: 21063368.
22. Mikaeloff Y, de Saint-Martin A, Mancini J, Peudenier S, Pedespan JM, Vallee L, et al. Topiramate: efficacy and tolerability in children according to epilepsy syndromes. Epilepsia 2003;53:225-32
23. Holland K, Wyllie E. Use of topiramte in localization related epilepsy in children. J Chlid Neurol 2000; 15(Suppl. 1):S3-6
24. Wheless JW. Use of topiramate in childhood generalized seizure disorders. j Child Neurol 2000;15(Suppl. 10:S7-S13.
25. Herranz JL, Arteaga R. Long-term efficacy and tolerance of topiramate in 44 children with resistant epilepsy. Rev Neurol 1999;28:1052-6.
26. Glauser TA, Miles MV, Tang P, Clark P, McGee K, Doose DR. Topiramate pharmacokinetics in infants. Epilepsia 1999;40:788-91.
27. Nieto-Barrera M, Candau R, nieto-Jimenez M, Correa A, del Portal LR. Topiramate in the treatment of severe myoclonic epilepsy in infancy. Seizure 2000;9:590-4.
Published
2021-09-30
How to Cite
1.
Haider S, Pervaiz K, Noor K, Fayyaz M, Nazir S, Ehtizaz L. The efficacy and safety of Topiramate in the Treatment of Refractory Epilepsy in children in Paediatric Neurology clinic at Izzat Ali Shah Hospital. JRMC [Internet]. 30Sep.2021 [cited 27Oct.2021];25(3):400-4. Available from: https://journalrmc.com/index.php/JRMC/article/view/1675